Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
114.37
+0.03 (0.03%)
Mar 20, 2026, 10:51 AM EDT - Market open
Arcellx Revenue
In the year 2025, Arcellx had annual revenue of $22.29M, down -79.35%. Arcellx had revenue of $1.65M in the quarter ending December 31, 2025, a decrease of -89.17%.
Revenue (ttm)
$22.29M
Revenue Growth
-79.35%
P/S Ratio
300.01
Revenue / Employee
$106,632
Employees
209
Market Cap
6.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.29M | -85.65M | -79.35% |
| Dec 31, 2024 | 107.94M | -2.38M | -2.16% |
| Dec 31, 2023 | 110.32M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Krystal Biotech | 389.13M |
| Rhythm Pharmaceuticals | 189.76M |
| Cytokinetics | 88.04M |
| Protagonist Therapeutics | 46.02M |
| Kymera Therapeutics | 39.21M |
ACLX News
- 1 day ago - Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 2 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 16 days ago - Top 2 Health Care Stocks That May Crash This Quarter - Benzinga
- 16 days ago - Baron Health Care Fund Q4 2025 Recent Activity - Seeking Alpha
- 16 days ago - Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha
- 24 days ago - Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
- 25 days ago - Why is Arcellx stock up 80% today? Gilead's $7.8B answer - Invezz
- 25 days ago - Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters